Search hospitals > Pennsylvania > Pittsburgh
UPMC-Saint Margaret
Claim this profilePittsburgh, Pennsylvania 15215
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Recurrence
156 reported clinical trials
24 medical researchers
Summary
UPMC-Saint Margaret is a medical facility located in Pittsburgh, Pennsylvania. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. UPMC-Saint Margaret is involved with conducting 156 clinical trials across 298 conditions. There are 24 research doctors associated with this hospital, such as Liza C. Villaruz, Adam Brufsky, MD, Melissa A. Burgess, and Dan P. Zandberg.Area of expertise
1Cancer
Global LeaderStage IV
Stage II
Stage III
2Breast Cancer
Global LeaderHER2 positive
ER positive
HER2 negative
Top PIs
Liza C. VillaruzUniversity of Pittsburgh Cancer Institute (UPCI)5 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
37 reported clinical trials
53 drugs studied
Adam Brufsky, MDUniversity of Pittsburgh Cancer Institute (UPCI)1 year of reported clinical research
Expert in Breast Cancer
Studies Cancer
31 reported clinical trials
70 drugs studied
Melissa A. BurgessUniversity of Pittsburgh Cancer Institute (UPCI)4 years of reported clinical research
Expert in Sarcoma
Studies Soft Tissue Sarcoma
23 reported clinical trials
42 drugs studied
Dan P. ZandbergUniversity of Pittsburgh Cancer Institute (UPCI)2 years of reported clinical research
Expert in Cancer
Expert in Squamous Cell Carcinoma
18 reported clinical trials
33 drugs studied
Clinical Trials running at UPMC-Saint Margaret
Breast Cancer
Prostate Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Squamous Cell Carcinoma
Renal Cell Carcinoma
Oropharyngeal Carcinoma
Small Cell Lung Cancer
Laryngeal Cancer
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Omitting Radiation Therapy
for Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at UPMC-Saint Margaret?
UPMC-Saint Margaret is a medical facility located in Pittsburgh, Pennsylvania. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. UPMC-Saint Margaret is involved with conducting 156 clinical trials across 298 conditions. There are 24 research doctors associated with this hospital, such as Liza C. Villaruz, Adam Brufsky, MD, Melissa A. Burgess, and Dan P. Zandberg.